Share Price and Basic Stock Data
Last Updated: February 10, 2026, 8:21 pm
| PEG Ratio | 5.10 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ajanta Pharma Ltd operates in the pharmaceuticals sector, focusing on the development and manufacture of specialty pharmaceutical products. The company reported a market capitalization of ₹34,810 Cr and a current share price of ₹2,786. For the fiscal year ending March 2025, Ajanta Pharma’s total sales stood at ₹4,648 Cr, reflecting an upward trend from ₹3,743 Cr in March 2023. The trailing twelve-month (TTM) revenue reached ₹4,973 Cr, indicating robust growth and a compound annual growth rate that outpaces many industry peers. Over the past few quarters, sales exhibited consistent growth, with the latest quarterly sales in September 2023 recording ₹1,028 Cr, up from ₹972 Cr in December 2022. This growth trajectory highlights the company’s effective market strategies and product demand, positioning it favorably within the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Ajanta Pharma’s profitability metrics demonstrate strong operational performance, with a net profit of ₹974 Cr for the fiscal year ending March 2025, compared to ₹588 Cr in March 2023. The company achieved an operating profit margin (OPM) of 27% for the same period, suggesting effective cost management and pricing strategies. The return on equity (ROE) stood at 24.9%, underscoring efficient capital utilization relative to shareholders’ equity. Furthermore, the interest coverage ratio (ICR) was exceptionally high at 65.32x, indicating that the company comfortably meets its interest obligations. However, the cash conversion cycle (CCC) of 246 days signals potential inefficiencies in working capital management, particularly in inventory and receivables, which could be areas for operational improvement.
Balance Sheet Strength and Financial Ratios
Ajanta Pharma’s balance sheet reflects a solid financial foundation, with total assets amounting to ₹5,672 Cr as of September 2025. The company reported reserves of ₹4,290 Cr, providing a buffer for future investments and challenges. Borrowings stood at ₹246 Cr, indicating low leverage and a conservative approach to debt, which is beneficial for financial stability. The price-to-book value (P/BV) ratio was recorded at 8.66x, signifying that the stock is priced at a premium relative to its book value, which can be interpreted as a sign of investor confidence in future growth. Additionally, the current ratio of 2.85x and quick ratio of 1.95x indicate healthy liquidity levels, positioning the company well to manage short-term liabilities effectively.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ajanta Pharma shows a stable ownership structure, with promoters holding 66.25% of the equity as of September 2025. This high level of promoter ownership often signals confidence in the company’s prospects. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), held 8.53% and 17.90% respectively, suggesting a moderate level of institutional backing. The public shareholding stood at 7.32%, indicating a relatively concentrated share base. The number of shareholders has fluctuated, with 67,785 shareholders reported in September 2025, reflecting a healthy interest from retail investors despite the concentration among promoters. This structure can foster a long-term growth perspective, although a more diverse shareholder base could enhance liquidity.
Outlook, Risks, and Final Insight
Looking ahead, Ajanta Pharma is well-positioned for growth, driven by its strong product portfolio and expanding market presence. The company’s commitment to research and development could yield new product offerings, enhancing revenue streams. However, risks remain, including potential regulatory challenges and competitive pressures in the pharmaceutical sector. Additionally, the relatively high cash conversion cycle could hinder operational efficiency if not addressed. Investors should remain vigilant regarding market dynamics and external economic factors that could impact performance. Overall, Ajanta Pharma’s strengths, including robust profitability and a solid balance sheet, coupled with its risks, present a nuanced investment landscape. Future performance will depend on the company’s ability to navigate these challenges while capitalizing on growth opportunities.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 102 | 184/84.3 | 28.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,684 Cr. | 338 | 479/192 | 77.1 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.4 Cr. | 42.2 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.8 Cr. | 54.5 | 54.5/17.0 | 190 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,100.98 Cr | 1,117.31 | 54.75 | 201.93 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 972 | 882 | 1,021 | 1,028 | 1,105 | 1,054 | 1,145 | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 |
| Expenses | 802 | 732 | 750 | 738 | 791 | 776 | 815 | 875 | 825 | 873 | 951 | 1,026 | 993 |
| Operating Profit | 170 | 149 | 271 | 291 | 314 | 278 | 330 | 311 | 321 | 297 | 351 | 328 | 382 |
| OPM % | 17% | 17% | 27% | 28% | 28% | 26% | 29% | 26% | 28% | 25% | 27% | 24% | 28% |
| Other Income | 35 | 37 | 32 | 21 | 14 | 36 | 26 | 19 | 30 | 18 | 26 | 59 | 25 |
| Interest | 3 | 1 | 1 | 2 | 2 | 2 | 1 | 6 | 8 | 6 | 5 | 3 | 5 |
| Depreciation | 33 | 33 | 33 | 34 | 34 | 34 | 34 | 34 | 36 | 40 | 41 | 43 | 44 |
| Profit before tax | 168 | 152 | 269 | 276 | 291 | 278 | 322 | 290 | 307 | 269 | 331 | 341 | 359 |
| Tax % | 20% | 20% | 23% | 29% | 28% | 27% | 24% | 25% | 24% | 16% | 23% | 24% | 24% |
| Net Profit | 135 | 122 | 208 | 195 | 210 | 203 | 246 | 216 | 233 | 225 | 255 | 260 | 274 |
| EPS in Rs | 10.50 | 9.54 | 16.24 | 15.24 | 16.39 | 15.82 | 19.68 | 17.33 | 18.64 | 18.03 | 20.44 | 20.83 | 21.91 |
Last Updated: February 6, 2026, 8:17 pm
Below is a detailed analysis of the quarterly data for Ajanta Pharma Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 1,375.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,354.00 Cr. (Sep 2025) to 1,375.00 Cr., marking an increase of 21.00 Cr..
- For Expenses, as of Dec 2025, the value is 993.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,026.00 Cr. (Sep 2025) to 993.00 Cr., marking a decrease of 33.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 382.00 Cr.. The value appears strong and on an upward trend. It has increased from 328.00 Cr. (Sep 2025) to 382.00 Cr., marking an increase of 54.00 Cr..
- For OPM %, as of Dec 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 24.00% (Sep 2025) to 28.00%, marking an increase of 4.00%.
- For Other Income, as of Dec 2025, the value is 25.00 Cr.. The value appears to be declining and may need further review. It has decreased from 59.00 Cr. (Sep 2025) to 25.00 Cr., marking a decrease of 34.00 Cr..
- For Interest, as of Dec 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Sep 2025) to 5.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Dec 2025, the value is 44.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.00 Cr. (Sep 2025) to 44.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 359.00 Cr.. The value appears strong and on an upward trend. It has increased from 341.00 Cr. (Sep 2025) to 359.00 Cr., marking an increase of 18.00 Cr..
- For Tax %, as of Dec 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 24.00%.
- For Net Profit, as of Dec 2025, the value is 274.00 Cr.. The value appears strong and on an upward trend. It has increased from 260.00 Cr. (Sep 2025) to 274.00 Cr., marking an increase of 14.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 21.91. The value appears strong and on an upward trend. It has increased from 20.83 (Sep 2025) to 21.91, marking an increase of 1.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:41 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,208 | 1,474 | 1,749 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | 4,973 |
| Expenses | 840 | 968 | 1,155 | 1,292 | 1,467 | 1,489 | 1,904 | 1,889 | 2,408 | 2,934 | 3,037 | 3,379 | 3,676 |
| Operating Profit | 369 | 505 | 594 | 691 | 658 | 567 | 683 | 1,001 | 933 | 808 | 1,172 | 1,269 | 1,297 |
| OPM % | 31% | 34% | 34% | 35% | 31% | 28% | 26% | 35% | 28% | 22% | 28% | 27% | 26% |
| Other Income | 14 | 8 | 14 | 20 | 24 | 21 | 88 | 24 | 112 | 74 | 85 | 85 | 134 |
| Interest | 9 | 6 | 5 | 1 | 0 | 1 | 12 | 8 | 10 | 6 | 7 | 21 | 23 |
| Depreciation | 44 | 52 | 44 | 61 | 60 | 72 | 96 | 116 | 125 | 131 | 135 | 144 | 160 |
| Profit before tax | 330 | 456 | 559 | 648 | 623 | 514 | 664 | 900 | 909 | 745 | 1,114 | 1,189 | 1,249 |
| Tax % | 29% | 32% | 26% | 22% | 25% | 25% | 30% | 27% | 22% | 21% | 27% | 23% | |
| Net Profit | 234 | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 | 974 |
| EPS in Rs | 17.75 | 23.47 | 31.49 | 38.40 | 35.50 | 29.56 | 35.73 | 50.38 | 55.63 | 45.89 | 63.70 | 73.68 | 77.94 |
| Dividend Payout % | 15% | 17% | 17% | 23% | 0% | 20% | 24% | 13% | 11% | 15% | 79% | 38% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 32.48% | 34.19% | 21.88% | -7.50% | -17.48% | 20.93% | 39.74% | 9.02% | -17.53% | 38.78% | 12.75% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1.71% | -12.32% | -29.37% | -9.99% | 38.41% | 18.81% | -30.72% | -26.55% | 56.31% | -26.03% |
Ajanta Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 12% |
| 3 Years: | 12% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 9% |
| TTM: | 9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 21% |
| 3 Years: | 25% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 22% |
| 3 Years: | 22% |
| Last Year: | 25% |
Last Updated: September 4, 2025, 10:30 pm
Balance Sheet
Last Updated: December 4, 2025, 12:55 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 25 | 25 | 25 | 25 |
| Reserves | 576 | 823 | 1,173 | 1,550 | 2,024 | 2,228 | 2,581 | 2,978 | 3,247 | 3,363 | 3,542 | 3,765 | 4,290 |
| Borrowings | 130 | 72 | 81 | 1 | 2 | 36 | 75 | 31 | 25 | 36 | 35 | 47 | 246 |
| Other Liabilities | 226 | 233 | 207 | 254 | 383 | 383 | 619 | 702 | 711 | 1,159 | 927 | 1,067 | 1,112 |
| Total Liabilities | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,904 | 5,672 |
| Fixed Assets | 279 | 288 | 451 | 589 | 1,053 | 1,178 | 1,472 | 1,541 | 1,512 | 1,496 | 1,479 | 1,762 | 1,873 |
| CWIP | 94 | 170 | 240 | 339 | 61 | 262 | 132 | 108 | 153 | 209 | 256 | 176 | 146 |
| Investments | 63 | 60 | 86 | 182 | 190 | 78 | 79 | 176 | 147 | 535 | 349 | 464 | 874 |
| Other Assets | 513 | 629 | 703 | 713 | 1,122 | 1,147 | 1,610 | 1,904 | 2,188 | 2,341 | 2,446 | 2,502 | 2,779 |
| Total Assets | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,904 | 5,672 |
Below is a detailed analysis of the balance sheet data for Ajanta Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,290.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,765.00 Cr. (Mar 2025) to 4,290.00 Cr., marking an increase of 525.00 Cr..
- For Borrowings, as of Sep 2025, the value is 246.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 47.00 Cr. (Mar 2025) to 246.00 Cr., marking an increase of 199.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,112.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,067.00 Cr. (Mar 2025) to 1,112.00 Cr., marking an increase of 45.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,672.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,904.00 Cr. (Mar 2025) to 5,672.00 Cr., marking an increase of 768.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,873.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,762.00 Cr. (Mar 2025) to 1,873.00 Cr., marking an increase of 111.00 Cr..
- For CWIP, as of Sep 2025, the value is 146.00 Cr.. The value appears to be declining and may need further review. It has decreased from 176.00 Cr. (Mar 2025) to 146.00 Cr., marking a decrease of 30.00 Cr..
- For Investments, as of Sep 2025, the value is 874.00 Cr.. The value appears strong and on an upward trend. It has increased from 464.00 Cr. (Mar 2025) to 874.00 Cr., marking an increase of 410.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,779.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,502.00 Cr. (Mar 2025) to 2,779.00 Cr., marking an increase of 277.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,672.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,904.00 Cr. (Mar 2025) to 5,672.00 Cr., marking an increase of 768.00 Cr..
Notably, the Reserves (4,290.00 Cr.) exceed the Borrowings (246.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 239.00 | 433.00 | 513.00 | 690.00 | 656.00 | 531.00 | 608.00 | -30.00 | 908.00 | 772.00 | -34.00 | -46.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 64 | 78 | 59 | 79 | 82 | 109 | 93 | 111 | 103 | 108 | 93 |
| Inventory Days | 164 | 159 | 180 | 186 | 315 | 415 | 276 | 434 | 347 | 283 | 283 | 308 |
| Days Payable | 132 | 109 | 128 | 157 | 224 | 214 | 202 | 212 | 143 | 147 | 159 | 155 |
| Cash Conversion Cycle | 94 | 114 | 130 | 88 | 170 | 282 | 184 | 315 | 315 | 240 | 233 | 246 |
| Working Capital Days | 39 | 56 | 78 | 65 | 103 | 113 | 108 | 126 | 140 | 83 | 119 | 97 |
| ROCE % | 55% | 57% | 52% | 46% | 34% | 24% | 27% | 32% | 29% | 23% | 32% | 32% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 1,674,471 | 0.68 | 463.64 | 1,977,744 | 2025-12-08 07:42:13 | -15.33% |
| UTI Flexi Cap Fund | 1,414,000 | 1.57 | 391.52 | 1,425,000 | 2026-01-25 06:31:44 | -0.77% |
| Kotak Small Cap Fund | 1,219,302 | 1.96 | 337.61 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 959,323 | 3.21 | 265.63 | 968,214 | 2025-12-08 04:19:42 | -0.92% |
| HDFC Large and Mid Cap Fund | 897,224 | 0.86 | 248.43 | N/A | N/A | N/A |
| Canara Robeco Large and Mid Cap Fund | 878,506 | 0.95 | 243.25 | 928,520 | 2026-01-25 01:39:51 | -5.39% |
| UTI Mid Cap Fund | 836,388 | 1.94 | 231.59 | 840,000 | 2026-01-25 06:31:44 | -0.43% |
| Nippon India Multi Cap Fund | 807,460 | 0.44 | 223.58 | 628,966 | 2025-12-08 02:19:27 | 28.38% |
| Canara Robeco Small Cap Fund | 698,037 | 1.48 | 193.28 | 579,013 | 2026-01-25 06:31:45 | 20.56% |
| Kotak Large & Midcap Fund | 500,000 | 0.46 | 138.45 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 73.56 | 64.82 | 45.89 | 82.45 | 75.09 |
| Diluted EPS (Rs.) | 73.53 | 64.77 | 45.89 | 82.45 | 75.09 |
| Cash EPS (Rs.) | 84.92 | 75.31 | 56.89 | 97.61 | 88.55 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 302.38 | 282.34 | 268.14 | 380.24 | 344.52 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 302.38 | 282.34 | 268.14 | 380.24 | 344.52 |
| Revenue From Operations / Share (Rs.) | 370.81 | 333.10 | 296.21 | 389.17 | 332.34 |
| PBDIT / Share (Rs.) | 108.02 | 99.45 | 69.80 | 121.72 | 117.83 |
| PBIT / Share (Rs.) | 96.52 | 88.73 | 59.45 | 107.13 | 104.48 |
| PBT / Share (Rs.) | 94.87 | 88.16 | 58.98 | 105.94 | 103.53 |
| Net Profit / Share (Rs.) | 73.43 | 64.60 | 46.54 | 83.01 | 75.20 |
| NP After MI And SOA / Share (Rs.) | 73.43 | 64.60 | 46.54 | 83.01 | 75.20 |
| PBDIT Margin (%) | 29.13 | 29.85 | 23.56 | 31.27 | 35.45 |
| PBIT Margin (%) | 26.02 | 26.63 | 20.06 | 27.52 | 31.43 |
| PBT Margin (%) | 25.58 | 26.46 | 19.91 | 27.22 | 31.15 |
| Net Profit Margin (%) | 19.80 | 19.39 | 15.71 | 21.33 | 22.62 |
| NP After MI And SOA Margin (%) | 19.80 | 19.39 | 15.71 | 21.33 | 22.62 |
| Return on Networth / Equity (%) | 24.28 | 22.87 | 17.35 | 21.83 | 21.82 |
| Return on Capital Employeed (%) | 30.10 | 29.95 | 21.21 | 26.98 | 29.02 |
| Return On Assets (%) | 18.35 | 17.59 | 12.56 | 17.57 | 17.30 |
| Asset Turnover Ratio (%) | 0.96 | 0.90 | 0.81 | 0.83 | 0.79 |
| Current Ratio (X) | 2.85 | 3.05 | 2.49 | 3.50 | 3.13 |
| Quick Ratio (X) | 1.95 | 2.12 | 1.77 | 2.28 | 1.94 |
| Inventory Turnover Ratio (X) | 5.37 | 1.14 | 1.19 | 1.10 | 1.25 |
| Dividend Payout Ratio (NP) (%) | 38.00 | 78.68 | 15.25 | 11.53 | 12.67 |
| Dividend Payout Ratio (CP) (%) | 32.85 | 67.48 | 12.47 | 9.81 | 10.76 |
| Earning Retention Ratio (%) | 62.00 | 21.32 | 84.75 | 88.47 | 87.33 |
| Cash Earning Retention Ratio (%) | 67.15 | 32.52 | 87.53 | 90.19 | 89.24 |
| Interest Coverage Ratio (X) | 65.32 | 174.28 | 151.01 | 102.45 | 123.89 |
| Interest Coverage Ratio (Post Tax) (X) | 45.40 | 114.20 | 101.68 | 70.87 | 80.07 |
| Enterprise Value (Cr.) | 32649.25 | 28149.11 | 14945.61 | 15321.67 | 15384.30 |
| EV / Net Operating Revenue (X) | 7.02 | 6.69 | 3.99 | 4.59 | 5.32 |
| EV / EBITDA (X) | 24.11 | 22.40 | 16.95 | 14.66 | 15.02 |
| MarketCap / Net Operating Revenue (X) | 7.06 | 6.72 | 4.08 | 4.65 | 5.40 |
| Retention Ratios (%) | 61.99 | 21.31 | 84.74 | 88.46 | 87.32 |
| Price / BV (X) | 8.66 | 7.93 | 4.51 | 4.76 | 5.21 |
| Price / Net Operating Revenue (X) | 7.06 | 6.72 | 4.08 | 4.65 | 5.40 |
| EarningsYield | 0.02 | 0.02 | 0.03 | 0.04 | 0.04 |
After reviewing the key financial ratios for Ajanta Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 73.56. This value is within the healthy range. It has increased from 64.82 (Mar 24) to 73.56, marking an increase of 8.74.
- For Diluted EPS (Rs.), as of Mar 25, the value is 73.53. This value is within the healthy range. It has increased from 64.77 (Mar 24) to 73.53, marking an increase of 8.76.
- For Cash EPS (Rs.), as of Mar 25, the value is 84.92. This value is within the healthy range. It has increased from 75.31 (Mar 24) to 84.92, marking an increase of 9.61.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 302.38. It has increased from 282.34 (Mar 24) to 302.38, marking an increase of 20.04.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 302.38. It has increased from 282.34 (Mar 24) to 302.38, marking an increase of 20.04.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 370.81. It has increased from 333.10 (Mar 24) to 370.81, marking an increase of 37.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 108.02. This value is within the healthy range. It has increased from 99.45 (Mar 24) to 108.02, marking an increase of 8.57.
- For PBIT / Share (Rs.), as of Mar 25, the value is 96.52. This value is within the healthy range. It has increased from 88.73 (Mar 24) to 96.52, marking an increase of 7.79.
- For PBT / Share (Rs.), as of Mar 25, the value is 94.87. This value is within the healthy range. It has increased from 88.16 (Mar 24) to 94.87, marking an increase of 6.71.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 73.43. This value is within the healthy range. It has increased from 64.60 (Mar 24) to 73.43, marking an increase of 8.83.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 73.43. This value is within the healthy range. It has increased from 64.60 (Mar 24) to 73.43, marking an increase of 8.83.
- For PBDIT Margin (%), as of Mar 25, the value is 29.13. This value is within the healthy range. It has decreased from 29.85 (Mar 24) to 29.13, marking a decrease of 0.72.
- For PBIT Margin (%), as of Mar 25, the value is 26.02. This value exceeds the healthy maximum of 20. It has decreased from 26.63 (Mar 24) to 26.02, marking a decrease of 0.61.
- For PBT Margin (%), as of Mar 25, the value is 25.58. This value is within the healthy range. It has decreased from 26.46 (Mar 24) to 25.58, marking a decrease of 0.88.
- For Net Profit Margin (%), as of Mar 25, the value is 19.80. This value exceeds the healthy maximum of 10. It has increased from 19.39 (Mar 24) to 19.80, marking an increase of 0.41.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 19.80. This value is within the healthy range. It has increased from 19.39 (Mar 24) to 19.80, marking an increase of 0.41.
- For Return on Networth / Equity (%), as of Mar 25, the value is 24.28. This value is within the healthy range. It has increased from 22.87 (Mar 24) to 24.28, marking an increase of 1.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 30.10. This value is within the healthy range. It has increased from 29.95 (Mar 24) to 30.10, marking an increase of 0.15.
- For Return On Assets (%), as of Mar 25, the value is 18.35. This value is within the healthy range. It has increased from 17.59 (Mar 24) to 18.35, marking an increase of 0.76.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.96. It has increased from 0.90 (Mar 24) to 0.96, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 2.85. This value is within the healthy range. It has decreased from 3.05 (Mar 24) to 2.85, marking a decrease of 0.20.
- For Quick Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has decreased from 2.12 (Mar 24) to 1.95, marking a decrease of 0.17.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 1.14 (Mar 24) to 5.37, marking an increase of 4.23.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 38.00. This value is within the healthy range. It has decreased from 78.68 (Mar 24) to 38.00, marking a decrease of 40.68.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 32.85. This value is within the healthy range. It has decreased from 67.48 (Mar 24) to 32.85, marking a decrease of 34.63.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.00. This value is within the healthy range. It has increased from 21.32 (Mar 24) to 62.00, marking an increase of 40.68.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 67.15. This value is within the healthy range. It has increased from 32.52 (Mar 24) to 67.15, marking an increase of 34.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 65.32. This value is within the healthy range. It has decreased from 174.28 (Mar 24) to 65.32, marking a decrease of 108.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 45.40. This value is within the healthy range. It has decreased from 114.20 (Mar 24) to 45.40, marking a decrease of 68.80.
- For Enterprise Value (Cr.), as of Mar 25, the value is 32,649.25. It has increased from 28,149.11 (Mar 24) to 32,649.25, marking an increase of 4,500.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.02. This value exceeds the healthy maximum of 3. It has increased from 6.69 (Mar 24) to 7.02, marking an increase of 0.33.
- For EV / EBITDA (X), as of Mar 25, the value is 24.11. This value exceeds the healthy maximum of 15. It has increased from 22.40 (Mar 24) to 24.11, marking an increase of 1.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 6.72 (Mar 24) to 7.06, marking an increase of 0.34.
- For Retention Ratios (%), as of Mar 25, the value is 61.99. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 61.99, marking an increase of 40.68.
- For Price / BV (X), as of Mar 25, the value is 8.66. This value exceeds the healthy maximum of 3. It has increased from 7.93 (Mar 24) to 8.66, marking an increase of 0.73.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 6.72 (Mar 24) to 7.06, marking an increase of 0.34.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ajanta Pharma Ltd:
- Net Profit Margin: 19.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 30.1% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 24.28% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 45.4
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.95
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 35.6 (Industry average Stock P/E: 54.75)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 19.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Ajanta House, Charkop, Kandivli (West), Mumbai Maharashtra 400067 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mannalal B Agrawal | Chairman |
| Mr. Madhusudan B Agrawal | Vice Chairman |
| Mr. Yogesh M Agrawal | Managing Director |
| Mr. Rajesh M Agrawal | Joint Managing Director |
| Mr. David Rasquinha | Independent Director |
| Ms. Medha Joshi | Independent Director |
| Mr. Rajesh Dalal | Independent Director |
| Ms. Simi Thapar | Independent Director |
FAQ
What is the intrinsic value of Ajanta Pharma Ltd?
Ajanta Pharma Ltd's intrinsic value (as of 11 February 2026) is ₹2642.66 which is 8.59% lower the current market price of ₹2,891.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹36,164 Cr. market cap, FY2025-2026 high/low of ₹3,021/2,022, reserves of ₹4,290 Cr, and liabilities of ₹5,672 Cr.
What is the Market Cap of Ajanta Pharma Ltd?
The Market Cap of Ajanta Pharma Ltd is 36,164 Cr..
What is the current Stock Price of Ajanta Pharma Ltd as on 11 February 2026?
The current stock price of Ajanta Pharma Ltd as on 11 February 2026 is ₹2,891.
What is the High / Low of Ajanta Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ajanta Pharma Ltd stocks is ₹3,021/2,022.
What is the Stock P/E of Ajanta Pharma Ltd?
The Stock P/E of Ajanta Pharma Ltd is 35.6.
What is the Book Value of Ajanta Pharma Ltd?
The Book Value of Ajanta Pharma Ltd is 345.
What is the Dividend Yield of Ajanta Pharma Ltd?
The Dividend Yield of Ajanta Pharma Ltd is 0.97 %.
What is the ROCE of Ajanta Pharma Ltd?
The ROCE of Ajanta Pharma Ltd is 32.4 %.
What is the ROE of Ajanta Pharma Ltd?
The ROE of Ajanta Pharma Ltd is 24.9 %.
What is the Face Value of Ajanta Pharma Ltd?
The Face Value of Ajanta Pharma Ltd is 2.00.